Mangoceuticals, Inc. announced definitive agreements with institutional investors for registered direct offering and private placements, expecting $2.5 million in gross proceeds.
The offerings involve sale of Common Units and pre-funded warrants at a price set by Nasdaq rules.
Proceeds will be used for general corporate purposes and working capital, alongside existing cash reserves.
Offerings Details
Sale of 1,930,502 Common Units and Pre-Funded Units, priced at $1.295 per Common Unit with exercise price at $1.4245.
Expected Proceeds
Aggregate gross proceeds from both transactions expected to be around $2.5 million.
Closing Date
Transactions anticipated to close on or about December 19, 2025, subject to customary closing conditions.
- The offerings provide Mangoceuticals with additional capital for operational needs and expansion.
- Securing investments through institutional investors enhances the company's financial stability and growth prospects.
Mangoceuticals' successful execution of the offerings underscores investor confidence in its business model and future prospects, setting a positive trajectory for continued growth and innovation in the men's health and wellness sector.